Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allergic bronchopulmonary aspergillosis.

Peter G Gibson1

  • 1Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, University of Newcastle, NSW, Australia. Peter.Gibson@hnehealth.nsw.gov.au

Seminars in Respiratory and Critical Care Medicine
|April 14, 2006
PubMed
Summary

Allergic bronchopulmonary aspergillosis (ABPA) is a serious lung condition caused by Aspergillus fumigatus. Treatment involves corticosteroids and antifungals to manage inflammation and airway damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of the 6-min walk test in adults with severe asthma.

Respiratory medicine·2025
Same author

Infant respiratory outcomes following asthma management and exacerbations in pregnancy.

ERJ open research·2025
Same author

Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts.

The Lancet. Respiratory medicine·2025
Same author

Digitally mapping the asthma journey-from diagnosis to remission.

EClinicalMedicine·2025
Same author

Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2025
Same author

Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).

The World Allergy Organization journal·2025

Area of Science:

  • Pulmonology
  • Immunology
  • Mycology

Background:

  • Allergic bronchopulmonary aspergillosis (ABPA) is an uncommon, severe respiratory disease.
  • It involves chronic airway inflammation and damage due to Aspergillus fumigatus.
  • ABPA is linked to bronchiectasis severity.

Purpose of the Study:

  • To describe the immunopathogenesis of ABPA.
  • To outline current treatment strategies for ABPA.
  • To emphasize comprehensive management of associated conditions.

Main Methods:

  • Review of immunopathogenic pathways in ABPA.
  • Analysis of inflammatory responses (Th2, eosinophilic, neutrophilic).
  • Summary of therapeutic interventions.

Related Experiment Videos

Main Results:

  • Aspergillus allergens trigger IL-5-mediated Th2 response, causing eosinophilic inflammation.
  • Aspergillus proteases induce epithelial activation and neutrophilic inflammation.
  • Intense airway inflammation leads to tissue damage, remodeling, and bronchiectasis.

Conclusions:

  • ABPA results from complex immune responses to Aspergillus fumigatus.
  • Effective treatment requires corticosteroids and oral azole antifungals.
  • Management must address severe asthma, bronchiectasis, and exacerbations.